Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study

Lena Flodin\textsuperscript{1,2} Maria Sää\textsuperscript{3} Tommy Cederholm\textsuperscript{4} Amer N Al-Ani\textsuperscript{2,5} Paul W Ackermann\textsuperscript{5,6} Eva Samnegård\textsuperscript{7} Nils Dalen\textsuperscript{7} Margareta Hedström\textsuperscript{2,5}

\textsuperscript{1}Department of Geriatric Medicine, Karolinska University Hospital Stockholm, Sweden; \textsuperscript{2}Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockholm, Sweden; \textsuperscript{3}Department of Endocrinology, Metabolism, and Diabetes, Karolinska University Hospital, Stockholm, Sweden; \textsuperscript{4}Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, Uppsala, Sweden; \textsuperscript{5}Department of Orthopedics, Karolinska University Hospital, Stockholm, Sweden; \textsuperscript{6}Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; \textsuperscript{7}Department of Clinical Science, Division of Orthopedics, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden

Background: After a hip fracture, a catabolic state develops, with increased bone loss during the first year. The aim of this study was to evaluate the effects of postoperative treatment with calcium, vitamin D, and bisphosphonates (alone or together) with nutritional supplementation on total hip and total body bone mineral density (BMD).

Methods: Seventy-nine patients (56 women), with a mean age of 79 years (range, 61–96 years) and with a recent hip fracture, who were ambulatory before fracture and without severe cognitive impairment, were included. Patients were randomized to treatment with bisphosphonates (risedronate 35 mg weekly) for 12 months (B; n=28), treatment with bisphosphonates along with nutritional supplementation (40 g protein, 600 kcal daily) for the first 6 months (BN; n=26), or to controls (C; n=25). All participants received calcium (1,000 mg) and vitamin D3 (800 IU) daily. Total hip and total body BMD were assessed with dual-energy X-ray absorptiometry at baseline, 6, and 12 months. Marker of bone resorption C-terminal telopeptide of collagen I and 25-hydroxy vitamin D were analyzed in serum.

Results: Analysis of complete cases (70/79 at 6 months and 67/79 at 12 months) showed an increase in total hip BMD of 0.7% in the BN group, whereas the B and C groups lost 1.1% and 2.4% of BMD, respectively, between baseline and 6 months (P=0.071, between groups). There was no change in total body BMD between baseline and 12 months in the BN group, whereas the B group and C group both lost BMD, with C losing more than B (P=0.009). Intention-to-treat analysis was in concordance with the complete cases analyses.

Conclusion: Protein-and energy-rich supplementation in addition to calcium, vitamin D, and bisphosphonate therapy had additive effects on total body BMD and total hip BMD among elderly hip fracture patients.

Keywords: hip fracture, nutritional supplementation, bisphosphonates, bone mineral density

Introduction

Inadequate intake of protein and total calories, leading to malnutrition, is common among hip fracture patients.\textsuperscript{1,2} After a hip fracture, a catabolic state develops, characterized by increased loss of bone mineral density (BMD) during the first year.\textsuperscript{3-5} Because protein is an important structural component of bone and previous studies have reported a positive association between protein intake and BMD/bone mineral content,\textsuperscript{6-8} it is tempting to hypothesize that protein and energy supplementation may slow down postoperative bone loss. One previous study showed that hip fracture patients who received postoperative supplemental protein suffered less loss of BMD in the proximal femur.
compared with controls at 12 months. Otherwise, there are few studies that have investigated the effect of nutritional supplementation on BMD after hip fractures.

Bisphosphonates are the most widely used drugs for treatment of osteoporosis and have been shown to reduce the risk for hip fracture. Risedronate, which was used in the present study, has previously been shown to increase BMD of the femoral neck and femoral trochanter in osteoporotic women aged 80 years and older after 6 months of treatment. Risedronate has not been studied for secondary prevention of bone loss in old adults after a hip fracture. However, beneficial effects on total hip BMD after hip fracture have been demonstrated, using zoledronic acid together with calcium and vitamin D.

The primary aim of this study was to investigate whether postoperative treatment with a combination of protein-rich formula and bisphosphonates can reduce BMD loss after hip fracture better than bisphosphonates alone. Secondary aims were to study treatment effects on the bone resorption marker C-terminal telopeptide of collagen I (serum CTX-I), serum levels of 25-hydroxy vitamin D (25OHD), and parathyroid hormone (PTH).

Methods
Patients
The study included a total of 79 patients with a mean age of 79 years (standard deviation, 9; range, 61–96 years) and a history of recent hip fracture (femoral neck or trochanteric) who were admitted to any of the four university hospitals in Stockholm. Inclusion criteria were age 60 years or older, no severe cognitive impairment (Short Portable Mental Questionnaire [see below] score, ≥3), ambulatory before fracture, and body mass index 28 kg/m² or lower. Exclusion criteria were pathological fractures and bisphosphate treatment within the last year. Patients with alcohol/drug abuse or overt psychiatric disorders were excluded. Also excluded were patients with abnormal hepatic or renal laboratory parameters such as serum-alanine aminotransferase or serum-ascpartate-aminotransferase twice the normal reference range or higher, respectively; serum-creatinine levels higher than 130 μmol/L or glomerular filtration rate lower than 30 mL/minute; or with bone metabolic disorders such as primary hyperparathyroidism, osteogenesis imperfecta, Paget’s disease, or myeloma. Patients with lactose intolerance, dysphagia, esophagitis, gastric ulcer, or malignancy were also excluded, as were patients with diabetes mellitus associated with nephropathy or retinopathy and patients with active iritis or uveitis.

Study design and intervention
Eligible patients who agreed to participate were randomized into three groups in blocks of twelve, using a sealed envelope technique, thereby ensuring equal distribution of patients in the three treatment groups at each center. Patients were followed-up for 12 months. All participants received 1,000 mg calcium and 800 IU vitamin D3 daily. The first group received 35 mg risedronate (Optinate® Septimum; Sanofi AB, Warner Chilcott, Weiterstadt, Germany) once weekly for 12 months (B; n=28). The second group received 35 mg risedronate once weekly for 12 months plus a nutritional supplement (Fresubin® protein energy drink; Fresenius Kabi, Bad Homburg, Germany) during the first 6 months after hip fracture (BN; n=26). The patients in the third group served as controls (C; n=25) and received calcium and vitamin D3 alone (Calcichew D3®; Takeda Pharmaceutical Company Limited, Osaka, Japan) for 12 months.

The supplement contained 150 kcal and 10 g protein/100 mL milk-based protein (80% casein and 20% whey). Patients were prescribed 200 mL twice daily, totaling 600 kcal with 40 g protein. Each study center was staffed by one physician and a trial nurse. The trial team was responsible for the randomization process, collection of morning blood samples 1–3 days postfracture, and ensuring that dual-energy X-ray absorptiometry (DXA) and all other examinations were carried out during the hospital stay.

Pharmacologic treatment and nutritional supplementation began as soon as patients were stable from a cardiovascular standpoint, able to take food by mouth, and able to sit in an upright position for 1 hour after taking their tablets.

Patients were instructed both verbally and in writing to take bisphosphonate 30 minutes before food and other medications. They were examined at baseline and again during follow-up at 6 and 12 months. About once a month, the research nurses interviewed patients by telephone regarding compliance, food intake, pain, and general state of health.

The study was conducted in compliance with the Helsinki Declaration and was approved by the local ethics committee in Stockholm. All participants provided written informed consent. (ClinicalTrials.gov: NCT01950169).

Measurements
BMD was measured by DXA, using either Hologic (Hologic, Inc., Waltham, MA, USA) or Ge Lunar (Madison, WI, USA) densitometers. BMD on the uninjured side (total hip) was assessed, as well as total-body BMD. Results were expressed as areal density (g/cm²) and as standard deviation in relation to both mean value among healthy young individuals.
found among the three treatment groups, other than the
other significant differences in baseline characteristics were
Results
Consolidated Standards of Reporting Trials guidelines.
and follow-up. In addition to analysis of complete cases, an
A paired-samples Student’s t-test was used to compare dif-
mences in serum-CTX-I within each group between baseline
Normal distribution of serum-CTX-I values was
used in the analysis of serum-PTH. The covariates used in
the analysis of serum-25OHD. Baseline value was the only covariate
of serum-25OHD. (nmol/L) was analyzed at baseline and again after 12 months,
using chemiluminescence immunoassays (Liaison® 25 OH vitamin D Total Assay; DiaSorin Inc., Stillwater, MN, USA).
To evaluate changes in bone turnover, serum CTX-I (ng/L) was
analyzed at baseline and at 12 months, using the Beta-
CrossLaps assay (Roche Diagnostics GmbH, Mannheim, Germany), a two-site immunometric (sandwich) assay based
on electro-chemiluminescence detection. The interassay
coefficient of variation was less than 20%. Patient height,
weight, and body mass index were monitored. Height was
measured in the supine position. Weight was calculated from
total mass (lean, fat, and bone mineral content), obtained
through DXA measurements. The examination also included
an appraisal of cognitive function using the Short Portable
Mental Questionnaire, including ten simple questions.15
Statistical methods
Calculations were performed using SPSS 22.0 for Windows
(IBM Corporation, Armonk, NY, USA). Descriptive sta-
tistics included mean, standard deviation, median, range,
and percentage. Differences between the three random-
ized treatment groups were analyzed using analysis of
covariance (ANCOVA). Covariates used in the analysis of
BMD were age, sex, total mass, and baseline BMD. Age
and baseline value were used as covariates in the analysis of
serum-25OHD. Baseline value was the only covariate
used in the analysis of serum-PTH. The covariates used in
the analysis of serum-CTX-I were age, sex, and baseline
value. Normal distribution of serum-CTX-I values was
achieved by transformation, using a logarithmic scale.
A paired-samples Student’s t-test was used to compare dif-
fferences in serum-CTX-I within each group between baseline
and follow-up. In addition to analysis of complete cases, an
intention-to-treat analysis was carried out16 in accordance with
Consolidated Standards of Reporting Trials guidelines.17
Results
No significant differences in baseline characteristics were
found among the three treatment groups, other than the
need for walking aids (Table 1). A total of 67 (85%) of
the original 79 patients presented for the final follow-up;
Figure 1 shows a patient flowchart. Among patients who
dropped out, average age was 87 years (standard deviation,
5; range, 78–94 years), mean value of total hip BMD was
0.650 g/cm² (standard deviation, 0.103), and total body BMD
was 0.943 g/cm² (standard deviation, 0.147).

Treatment adherence
Among the control patients, 17 of 24 patients who presented
at 12 months took calcium and vitamin D as prescribed.
In group B, 18 of 25 presenting patients took their daily
dose of calcium and vitamin D, and 18 of 25 took the bis-
phosphonate as stipulated. In group BN, seven of 18 corre-
sponding patients complied with the drugs and nutritional
supplement prescription; the remaining eleven patients
reported an intake of half the prescribed nutritional
supplement. Three of these patients also reported a lower
intake of prescribed bisphosphonate, and two took only
half the prescribed daily dose of calcium and vitamin D.
In total, 15 patients in the BN group took the bisphospho-
name as stipulated.
Three patients in the control group and two in the
group B reported gastrointestinal complaints (either constipa-
tion or diarrhea). A dose reduction was made for one patient
with hypercalcemia in group C.

Effects on BMD and bone turnover
Seventy-nine patients were measured by DXA at inclu-
sion, 68 patients at 6 months, and 66 at 12 months. Because
of a total hip replacement on the uninjured side, nine patients
could not be measured at the hip.
During the first 6 months, total hip BMD increased by
0.7% in the BN group, whereas groups B and C showed losses
of 1.1% and 2.4%, respectively (P by ANCOVA =0.071;
Table 2; Figure 2).
On average, there was no loss in total body BMD between
baseline and 12 months in the BN group (Table 2). More-
over, both the B and C groups lost BMD, and this loss was
greater among controls than in group B (P=0.009; Table 2;
Figure 3).
There was a trend for difference between groups, accord-
ing to change in the bone resorption marker serum-CTX-I
(P=0.055; Table 2). Within-group analysis showed a signifi-
cant decrease in the serum-CTX-I marker of 33% and 36%
in groups B and BN, respectively (P<0.001), whereas the
smaller decrease of 12% in the C group was not significant
(P=0.77).
Identified lack of compliance in eleven of the 18 patients with serum-25OHD concentrations that were lower than 50 nmol/L. We observed that 26% of the patients still had serum-25OHD concentrations lower than 25 nmol/L at the 12-month follow-up, while 11 patients had values lower than 25 nmol/L at baseline. Among them, eleven had values lower than 25 nmol/L at baseline. At the 12-month follow-up, 26% of the patients still had serum-25OHD concentrations lower than 50 nmol/L. We identified lack of compliance in eleven of the 18 patients who failed to normalize their concentration of serum-25OHD.

Levels of 25OHD and parathyroid hormone

During the study, there was a mean increase in serum-25OHD of between 17 nmol/L and 20 nmol/L in all three groups. Mean serum-25OHD concentrations in groups B and BN were below normal (ie, <50 nmol/L at baseline) but had normalized by the 12-month follow-up (Tables 1 and 2). In total, 59% of the patients had a baseline concentration of serum-25OHD that was lower than 50 nmol/L. Among them, eleven had values lower than 25 nmol/L. At the 12-month follow-up, 26% of the patients still had serum-25OHD concentrations that were lower than 50 nmol/L. We identified lack of compliance in eleven of the 18 patients who failed to normalize their concentration of serum-25OHD.

Intention-to-treat analysis

The primary analysis population was used to replace missing data, and the secondary analysis population was used as a sensitivity analysis and showed the following results. The percentage change in total hip BMD between baseline and 6 months was +0.9% in the BN group and −0.5%
and -2.7% in the B and C groups, respectively (P=0.03). The corresponding changes between baseline and 12 months were -0.8% for the BN group and -1.7% and -2.6% for the B and C groups, respectively (P=0.279).

According to the sensitivity analysis, the percentage change in total body BMD between baseline and 6 months was -0.7% for the BN group and -0.7% and -1.3% for the B and C groups, respectively (P=0.436). Between baseline and 12 months, the percentage change in total body BMD was -0.02% for the BN group and -0.9% and -1.6% for the B and C groups, respectively (P=0.030).

The sensitivity analysis confirmed the trend indicated by the results, showing a more pronounced decrease in serum-CTX-I in the B and BN groups than in the C group (P=0.019). The sensitivity analysis was in line with the results for complete cases, showing no significant differences among the three groups in changes of serum-25OHD and serum-PTH at either 6- or 12-month follow-up.

**Discussion**

We found that nutritional supplementation, in addition to calcium, vitamin D, and risedronate, had a positive effect on total hip BMD and total body BMD in elderly patients with a recent hip fracture. An annual loss of 0.27% and 0.25% of total hip BMD in women and men, respectively, has been reported for a healthy population, aged 50–85 years. However, prior studies have shown a much higher loss, at 2.0%–4.6% (hip BMD), the first year after hip fracture, which is consistent with the findings for the control group in the current study. Two studies reported an increase in total hip BMD after hip fracture when patients were treated with a single dose of intravenous zoledronic acid. The present study entailed bisphosphonates orally but still had bone-resorption-preventive effects compared with controls. Because absorption of orally administered treatment is low even under ideal circumstances, it could explain the lower net gain in BMD compared with the previous studies. Another important consideration is known suboptimal patient adherence with orally administered bisphosphonates, which we also observed in the current study.

To our knowledge, only a few studies have explored the possible effects of protein- and energy-rich nutritional supplements on BMD after a hip fracture. In a randomized controlled study of 60 women with femoral neck fracture, Tengstrand et al evaluated the effect of treatment with protein-rich supplementation alone or in combination with
anabolic steroids on both hip and total body BMD. Although the difference in BMD between the groups did not reach statistical significance, the results of their study indicated an increase in total body BMD at 6 and 12 months in the groups that received protein and energy supplementation compared with the group treated only with calcium and vitamin D. Furthermore, participants in our study were supplemented with 600 kcal/day, rather than the 250 kcal/day seen in one of the previous studies. Unlike previous studies, patients in the current study were also treated with drugs that inhibit bone resorption. The mean change in total hip BMD between groups at 6 months did not quite reach significance, but this may be explained by the small group size. However, the intention-to-treat analysis supported the results of complete cases and showed significant difference between groups in total hip BMD at 6 months and total body BMD at 12 months. The more rapid bone metabolic changes in total hip BMD could be a result of a larger content of trabecular bone compared with total body BMD. It may also explain the lack of

**Figure 2** Total hip bone mineral density (BMD) in absolute values (g/cm²) at baseline and at follow-up. 
**Abbreviations:** C, control; B, bisphosphonates; BN, bisphosphonates plus nutritional supplementation.

**Figure 3** Total body bone mineral density (BMD) in absolute values (g/cm²) at baseline and at follow-up. 
**Abbreviations:** C, control; B, bisphosphonates; BN, bisphosphonates plus nutritional supplementation.

### Table 2 Mean change in BMD and biochemical measurements among patients presenting for follow-up at 6 and 12 months

<table>
<thead>
<tr>
<th>Months</th>
<th>Group C, mean (SD), %</th>
<th>Group B, mean (SD), %</th>
<th>Group BN, mean (SD), %</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BMD total hip, g/cm²</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–6†</td>
<td>-0.017 (0.026), -2.4</td>
<td>-0.008 (0.037), -1.1</td>
<td>0.005 (0.026), +0.7</td>
<td>0.071</td>
</tr>
<tr>
<td>0–12†</td>
<td>-0.018 (0.032), -2.6</td>
<td>-0.012 (0.042), -1.7</td>
<td>-0.004 (0.025), -0.5</td>
<td>0.239</td>
</tr>
<tr>
<td></td>
<td>BMD total body, g/cm²</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–6†</td>
<td>-0.012 (0.019), -1.2</td>
<td>-0.005 (0.018), -0.5</td>
<td>-0.006 (0.018), -0.6</td>
<td>0.429</td>
</tr>
<tr>
<td>0–12‡‡</td>
<td>-0.017 (0.020), -1.8</td>
<td>-0.003 (0.022), -0.3</td>
<td>0.0006 (0.019), +0.06</td>
<td>0.009</td>
</tr>
<tr>
<td>0–12²²</td>
<td>-86 (291)</td>
<td>-188 (249)</td>
<td>-145 (134)</td>
<td></td>
</tr>
<tr>
<td>0–12²²</td>
<td>-0.2 (0.7)</td>
<td>-0.6 (0.7)</td>
<td>-0.6 (0.5)</td>
<td>0.055</td>
</tr>
<tr>
<td>0–12²²</td>
<td>17 (22)</td>
<td>18 (37)</td>
<td>20 (24)</td>
<td>0.730</td>
</tr>
<tr>
<td>S-CTX-I ng/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–12††</td>
<td>-2.3 (19.4)</td>
<td>7.4 (16.3)</td>
<td>-8.6 (17.9)</td>
<td>0.453</td>
</tr>
<tr>
<td>0–12††</td>
<td>3.0 (18.4)</td>
<td>-4.7 (19.8)</td>
<td>-2.2 (18.2)</td>
<td>0.494</td>
</tr>
</tbody>
</table>

**Notes:** † Differences between groups were analyzed by analysis of covariance. ‡ Missing data: BMD total hip 0–6 months in group C, B, BN = 2, 8, 9, respectively. § Missing data: BMD total body 0–6 months in group C, B, BN = 1, 3, 7. ¶ Missing data: BMD total body 0–12 months in group C, B, BN = 2, 3, 8. ¶¶ Missing data: CTX 0–12 months in group C, B, BN = 1, 3, 7. ‡‡ Missing data: 25OH vitamin D in group C, B, BN = 1, 3, 7. ‡‡‡ Missing data: parathyroid hormone 0–12 months in group C, B, BN = 3, 6, 9.

**Abbreviations:** C, control; B, bisphosphonates; BN, bisphosphonates plus nutritional supplementation; SD, standard deviation; BMD, bone mineral density; S-CTX-I, serum C-terminal telopeptide of collagen I; S-25OH-D, serum-25-hydroxy-vitamin D; S, serum.

**Abbreviations:** C, control; B, bisphosphonates; BN, bisphosphonates plus nutritional supplementation; SD, standard deviation; BMD, bone mineral density; S-CTX-I, serum C-terminal telopeptide of collagen I; S-25OH-D, serum-25-hydroxy-vitamin D; S, serum.
effect on total hip BMD at 12 months because treatment with nutritional supplementation ended at 6 months. Although the study lasted for 1 year, we chose to give nutritional supplement only during the first 6 postoperative months, when the degree of catabolism is likely to be most pronounced.

We found no differences in vitamin D levels between groups to explain the disparities in BMD. All groups received vitamin D, and mean values were normalized during the study. However, 26% of all patients included still had values less than 50 nmol/L at the final follow-up; these findings were consistent with the results from a prior study in which hospitalized women at 66–95 years of age were treated with vitamin D3 (800 IE) and calcium (1,000 mg).23 As in the current study, mean levels were normalized after treatment, but in 18 (35%) of 51 patients, the levels remained low.23 Reasons proposed to explain these findings included insufficient vitamin D dose, a short supplementation period of only 3 months, and noncompliance issues. The first and last of these reasons may also apply to the current study.

The decrease in bone resorption marker serum-CTX-I levels became more pronounced in both risendronate-treated groups at 12 months. Because bone resorption-inhibiting drugs decrease CTX-I levels, these results reflect the expected treatment response to risendronate. Our baseline samples were drawn 1–3 days postfracture, which may have contributed to the variability in CTX-I levels. Other causes of variability not taken into account in the current study include food intake and circadian rhythm.24

Potential limitations of our study were the inclusion and exclusion criteria, which selected for a group of hip fracture patients who were living independently, were ambulatory on admission, were without severe cognitive dysfunction, and were slightly younger than the average age for this particular diagnosis. Group size was also a limiting factor, as was lack of compliance despite regular telephone follow-ups. The randomized design was one of the strengths of the study, as was the relatively long treatment period. Moreover, the design of the current study was novel in that it combined nutritional supplementation with bisphosphonate treatment after hip fracture in elderly men and women.

We may thereby conclude that nutritional supplementation, along with an orally administered bisphosphonate, produces additive effects on BMD after hip fracture.

Acknowledgments
The authors are grateful to research nurses Paula Kelly-Pettersson, Bodil Samuelsson, Åsa Norling, Kristina Källbom, Elisabeth Skogman, Anita Söderqvist, and Christina Häll and to Jan Kowalski for the assistance with statistical analysis. The study received unrestricted financial support from Stockholm County Council. The grants covered the costs of trial nurses at the four participating centers. Financial support was also provided by Karolinska Institutet funding and through the regional agreement on medical training and clinical research between Stockholm County Council and Karolinska Institutet.

Disclosure
The bisphosphonate preparation risendronate (Optinate® Septimum) was provided by Sanofi AB (Weiterstadt, Germany) and the liquid supplementation was provided by Fresenius Kabi (Bad Homburg, Germany). Sponsors were not involved in the planning or implementation of the study, nor in the analyses, conclusions, or manuscript writing. None of the authors of this manuscript has any conflict of interest regarding funding sources. All authors contributed significantly to the implementation of the study, data analysis, and manuscript writing.

References


